09/22/23 6:23 PMNasdaq : ACAD Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Acadia Pharmaceuticals Inc. today announced that on September 8, 2023, the Compensation Committee of Acadia’ s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,749 shares of common stock and 14,306 restricted stock units to 14 new employees under Acadia’ s 2023 Inducement Plan. The Compensation...RHEA-AIvery positive
09/19/23 4:05 PMNasdaq : ACAD managementAcadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate CommunicationsAcadia Pharmaceuticals Inc. today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’ s Executive Management Committee. Kildani earned a bachelor’ s degree in...RHEA-AIneutral
08/30/23 4:05 PMNasdaq : ACAD conferencesAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesAcadia Pharmaceuticals Inc. today announced that it will participate at the following upcoming investor conferences:. Citi's 18 th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1 x1 Meetings Morgan Stanley 21 st Annual Global Healthcare Conference Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern...RHEA-AIneutral
08/14/23 4:05 PMNasdaq : ACAD Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Acadia Pharmaceuticals Inc. today announced that on August 1, 2023, the Compensation Committee of Acadia’ s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,612 shares of common stock and 14,990 restricted stock units to 16 new employees under Acadia’ s 2023 Inducement Plan. The Compensation...RHEA-AIvery positive
08/02/23 4:05 PMNasdaq : ACAD earningsAcadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating OverviewAcadia Pharmaceuticals Inc. today announced its financial results for the second quarter ended June 30, 2023.. “Our second quarter 2023 results reflect strong performances from both commercial franchises. Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023, and were $283.7 million for the...RHEA-AIneutral
08/01/23 7:30 PMNasdaq : ACAD Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Acadia Pharmaceuticals Inc. today announced that on July 18, 2023, the Compensation Committee of Acadia’ s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of common stock and 11,988 restricted stock units to 16 new employees under Acadia’ s 2023 Inducement Plan. The Compensation Committee...RHEA-AIvery positive
07/24/23 4:05 PMNasdaq : ACAD managementAcadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business OfficerAcadia Pharmaceuticals Inc. announced today the appointment of Dr. Oliver served as SVP, Head of Global Business Development& Licensing and Alliance Management, as well as Chief Operations Officer, U.S. and Europe at Simcere Pharmaceutical Group. Oliver.“ The recent success of DAYBUE, originally partnered for North America in 2018, together with the recent...RHEA-AIneutral
07/19/23 4:04 PMNasdaq : ACAD earningsAcadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023Acadia Pharmaceuticals Inc. today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets. Acadia’ s management team will also host a conference call and webcast on August 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will...RHEA-AIneutral
07/13/23 4:05 PMNasdaq : ACAD acquisitionAcadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X SyndromeIn addition to expanding access to trofinetide outside of North America, this agreement gives Acadia exclusive worldwide rights to NNZ-2591 in both Rett syndrome and Fragile X syndrome. This deal also enables Acadia to leverage insights from our successful U.S. launch of DAYBUE in other global territories. Acadia intends to submit a New Drug Submission for...RHEA-AIneutral
06/26/23 5:00 PMNasdaq : ACAD Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Acadia Pharmaceuticals Inc. today announced that on June 13, 2023, the Compensation Committee of Acadia’ s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 153,615 shares of common stock and 56,399 restricted stock units to 28 new employees under Acadia’ s 2023 Inducement Plan. The Compensation...RHEA-AIvery positive